HEALTH● LOWAug 26 · Aug 26, 2026, 11:55 AM
Summit rises as lead drug from Akeso outperforms Astra’s Imfinzi in late-stage trial
Seeking Alpha Tech
A drug called Summit, developed by Akeso, has reportedly outperformed Astra's Imfinzi in a late-stage trial. This indicates a significant development in pharmaceutical competition.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH11m agoEbola: We Have A problem With Delayed Diagnosis, Resources To Cope — Medical DoctorChannels TVHEALTHBREAKING18m agoNigeria records its first Ebola case amid rapid regional spreadFrance 24 [en]HEALTH23m agoRoivant to seek label expansion for Lisraya in uveitis after late-stage trial winSeeking Alpha TechHEALTH25m agoNeurologist on multiple sclerosis warning signs to look out forCBS News